


**Agenda**  
**Subgroup on Parasites**  
*7 July 2012, 14:00 – 16:00*  
*Fiesta Americana Grand Coral Hotel*  
*Room Coral Sea*

**14:00 – 14:30**


**Report on Subgroup Activities**

*David Leiby*


- Parasite Survey accepted as an International Forum
  - thanks to Henk Reesink and Desanka Heidsieck
  - handled similarly to recent NAT survey
  - guest editorship with inclusion of collaborators




- Completion and distribution of survey
  - given nature of parasitic infections sought broader distribution range than normal IF normal
  - additional contacts provided by ISBT members
  - will seek additional coverage as needed
  - English and Spanish versions
  
- Summary of survey results to date
  - historical accounting of TTP
  - worldwide mitigation approaches
    - deferrals
    - testing
    - pathogen reduction
    - etc.



# Survey Distribution



# Surveys Returned to Date




**14:30 – 14:50**

## **Update on *Babesia microti* mitigation efforts the United States**


*David Leiby et al.*

- **current status of TTB in U.S.**
  - 162+ cases of TTB (Herwaldt et al., 2011)
    - 159 cases attributable to *B. microti*
    - 3 cases attributable to *B. duncani*
  - babesiosis now nationally notifiable via CDC
  - deferral for “History of Babesiosis”
    - largely ineffective
  - absence of blood screening assay
  - BPAC supports concept of regionalized screening
  - several investigations currently under IND



## Current Studies Under IND

- Rhode Island Blood Center/Imugen
  - selective testing
  - initial data published
- American Red Cross/Imugen
  - retrospective and prospective testing
- BSRI/Immunitics
  - assay development
  - clinical trials
- Other studies involving Imugen




**14:50 – 15:10**

**Presentation: *Babesia* in Australia –  
implications for blood safety**

*Clive Seed*

- first case of human babesiosis described in Australia
- etiologic agent – *Babesia microti*
  - confirmed by molecular methods
- *Ixodes* vector present in Australia
  - specific vector not identified in this case
- limited current impact in Australia
- incomplete understanding of distribution of *Babesia* spp.  
worldwide




**15:10 – 15:30**

**Presentation: Efficacy of Mirasol  
treatment of whole blood spiked with  
*Plasmodium falciparum* with both  
molecular and functional endpoints**

*J.P. Allain/Mira El Chaar*

- efficacy of pathogen reduction demonstrated
- examined by molecular methods and parasite viability
  - not readily comparable
- discussed issues of experimental vs. “real” infection levels





**15:30 – 16:00**

**Report on Malaria Risk Project (jointly  
with Subgroup on Epidemiology and  
Surveillance)**

*Sheila O'Brien*

- summary provided by Sheila in Subgroup on  
Epidemiology and Surveillance report

